Development of a TRBC2 binder will now allow the possibility of targeting nearly all cases of mature T cell lymphomas, with TRBC1/2 based therapeutics opening the possibility of a widely applicable immunotherapeutic approach in this area of unmet medical need. This evidence concerns the gene TRBC1 and T-cell non-Hodgkin lymphoma.